Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, ETH Zurich, 8093 Zurich, Switzerland.
Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland.
Hum Mol Genet. 2020 May 28;29(8):1253-1273. doi: 10.1093/hmg/ddaa034.
Some mutations affecting dynamin 2 (DNM2) can cause dominantly inherited Charcot-Marie-Tooth (CMT) neuropathy. Here, we describe the analysis of mice carrying the DNM2 K562E mutation which has been associated with dominant-intermediate CMT type B (CMTDIB). Contrary to our expectations, heterozygous DNM2 K562E mutant mice did not develop definitive signs of an axonal or demyelinating neuropathy. Rather, we found a primary myopathy-like phenotype in these mice. A likely interpretation of these results is that the lack of a neuropathy in this mouse model has allowed the unmasking of a primary myopathy due to the DNM2 K562E mutation which might be overshadowed by the neuropathy in humans. Consequently, we hypothesize that a primary myopathy may also contribute to the disease mechanism in some CMTDIB patients. We propose that these findings should be considered in the evaluation of patients, the determination of the underlying disease processes and the development of tailored potential treatment strategies.
一些影响动力蛋白 2(DNM2)的突变可导致显性遗传性腓骨肌萎缩症(CMT)神经病。在这里,我们描述了携带 DNM2 K562E 突变的小鼠的分析,该突变与显性中间型 CMT 型 B(CMTDIB)有关。与我们的预期相反,杂合子 DNM2 K562E 突变小鼠并未出现明确的轴索性或脱髓鞘性神经病的迹象。相反,我们在这些小鼠中发现了一种原发性肌病样表型。对这些结果的一种可能解释是,由于 DNM2 K562E 突变导致的原发性肌病在这种小鼠模型中没有神经病,因此可能被人类的神经病所掩盖。因此,我们假设原发性肌病也可能导致一些 CMTDIB 患者的疾病机制。我们提出,这些发现应在患者评估、确定潜在疾病过程以及制定针对性的潜在治疗策略中加以考虑。